Standard treatment with bevacizumab as targeted therapy in cervical cancer

Enríquez-Aceves, Isabel; Galicia-Carmona, Tatiana; Coronel-Martínez, Jaime A.; Espinosa-Romero, Raquel; Calderillo-Ruíz, Germán; Cortés-Esteban, Patricia; Cetina-Pérez, Lucely.
Rev. invest. clín ; 72(4): 213-218, Jul.-Aug. 2020.
Artículo en Inglés | LILACS | ID: biblio-1251858

Documentos relacionados

  1. STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER.
  2. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
  3. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
  4. Reducing Treatment Burden in AMD.
  5. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
  6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
  7. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer.
  8. Off-label use of intravitreal bevacizumab: A global conundrum.
  9. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
  10. Bevacizumab for the treatment of neovascular age-related macular degeneration.